首页 文献索引 SCI期刊 AI助手
条件筛选
相关性 最新发表 最早发表
全文 标题 期刊 作者
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
模糊 精准
{{tag.shortname||tag.name}}:{{getFilterLabel(field)}} Clear All
Kirbi Yelorda,Heather Day,M Katherine Arnow et al. Kirbi Yelorda et al.
Objective: To examine associations of individual and cumulative multiple, co-occurring individual-level social risk factors with long-term cancer-specific survival among patients with advanced colorectal cancer....Conclusion: Cumulative social risk was associated with long-term cancer-specific survival after treatment for Stage III colorectal cancer.
Jingkun Shang,Jinlai Wei Jingkun Shang
exhibited significantly poorer outcomes across multiple survival metrics: overall survival (HR = 1.73; 95%CI: 1.50-2.01; P < 0.01; I 2 = 62%), recurrence-free survival (HR = 1.51; 95% CI: 1.22-1.87; P < 0.01; I 2 = 14%), disease-free survival (HR = 1.61; 95% CI: 1.33-1.95; P < 0.01; I 2 = 35%), and cancer-specific...survival (HR = 3.94; 95% CI: 2.34-6.62; P < 0.01; I 2 = 0%).
Alejandro Calvillo-Ramirez,Lauren Chew,Laura Davis et al. Alejandro Calvillo-Ramirez et al.
Primary outcomes were cancer-specific survival (CSS), estimated glomerular filtration rate (eGFR) changes, and postoperative eGFR. Secondary outcomes included overall survival (OS), recurrence-free survival (RFS), and metastasis-free survival (MFS).
Simon U Engelmann,Christoph Pickl,Maximilian Haas et al. Simon U Engelmann et al.
In bladder cancer (BC) patients, higher IL-6 serum levels have been linked with adverse pathologic features, worse overall survival (OS) and cancer-specific survival (CSS). IL-6 is being investigated as a therapeutic target. However, concentrations in tumor-tissue are not investigated in detail.
Mattia Longoni,Andrea Marmiroli,Fabian Falkenbach et al. Mattia Longoni et al.
Introduction: We hypothesized that, within organ-confined (OC, T2N0M0) non-urothelial carcinoma of urinary bladder (non-UCUB) patients, trimodal therapy (TMT) use does not differ from radical cystectomy (RC) regarding can...
Sehyeon Yu,Hye-Sung Jo,Young-Dong Yu et al. Sehyeon Yu et al.
In long-term outcomes, the overall survival (OS) and cancer-specific survival (CSS) were significantly better in the curative group compared to the non-curative group (p < 0.001, both).
Ruisheng Huang,Jian Chen,Limin Lin et al. Ruisheng Huang et al.
Objective: To develop a nomogram that accurately predicts cancer-specific survival (CSS) in patients with ocular melanoma (OM)....Conclusion: We developed a nomogram that can be used to predict the 3, 5 and 8 years cancer-specific survival (CSS) rates for patients diagnosed with OM.
Silpa Raju-Salicki,Hayley B Stowe,Alden D&#x;Souza et al. Silpa Raju-Salicki et al.
Breast cancer-specific survival (BCSS) was 99.6% at the time of analysis. There was no statistically significant difference in overall survival or recurrence rates between the different treatment modalities.
Mariko Kurokawa,Wataru Gonoi,Shouhei Hanaoka et al. Mariko Kurokawa et al.
The effects of body composition parameters and clinical data on overall survival (OS) and cancer-specific survival (CSS) were analyzed.
耗时 0.14566 秒,为您在 48229835 条记录里面共找到 9581 篇文章 [XML]